Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; p. viii400
Main Authors Hale, D.F., Mittendorf, E.A., Brown, T.A., Clifton, G.T., Vreeland, T.J., Myers, J., Peace, K., Jackson, D., Greene, J., Holmes, J., Peoples, G.E.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text

Cover

Author Holmes, J.
Mittendorf, E.A.
Greene, J.
Peoples, G.E.
Myers, J.
Hale, D.F.
Clifton, G.T.
Peace, K.
Jackson, D.
Vreeland, T.J.
Brown, T.A.
Author_xml – sequence: 1
  givenname: D.F.
  surname: Hale
  fullname: Hale, D.F.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 2
  givenname: E.A.
  surname: Mittendorf
  fullname: Mittendorf, E.A.
  organization: Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA
– sequence: 3
  givenname: T.A.
  surname: Brown
  fullname: Brown, T.A.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 4
  givenname: G.T.
  surname: Clifton
  fullname: Clifton, G.T.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 5
  givenname: T.J.
  surname: Vreeland
  fullname: Vreeland, T.J.
  organization: Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA
– sequence: 6
  givenname: J.
  surname: Myers
  fullname: Myers, J.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 7
  givenname: K.
  surname: Peace
  fullname: Peace, K.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 8
  givenname: D.
  surname: Jackson
  fullname: Jackson, D.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 9
  givenname: J.
  surname: Greene
  fullname: Greene, J.
  organization: General Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX, USA
– sequence: 10
  givenname: J.
  surname: Holmes
  fullname: Holmes, J.
  organization: Medical Oncology, Naval Medical Center San Diego, San Diego, CA, USA
– sequence: 11
  givenname: G.E.
  surname: Peoples
  fullname: Peoples, G.E.
  organization: Metis Foundation, CVDP, San Antonio, TX, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32137003$$D View this record in MEDLINE/PubMed
BookMark eNp9Uctu1TAQtVARvS18ABs0y1YorR-Jk4hVVRV6pQoQr23k2JPWKHEi27n09pv5iDpKQWLDZiyNz2N0zhE5cKNDQl4zesZoLc6VSwt9Ppg9r6ozStkzsmGFrLOK5uyAbGjNRVYWIj8kRyH8pJTKmtcvyKHgTJSUig35_dljFibUtrNowLqI3g6gnOr3wQYYO1DglTPjYB8SYLpTAWG7bSF6q_rlP3oV4vwwD6qFt-CwtxNO0Q5zzL7CyUecf6j7U9iFf4Dd6CHeIUwed-iiHd0i5VHP3qPTCAaH0YVEiRigRYedjem8xXbqMdncqmh3CCfXV1849OOvDO-TWAjW3Z5C6zF5gVZJysOUoMkkvCTPO9UHfPX0HpPv76--XV5nN58-bC8vbjLNy4plecu55DKvSlPqgileou5UmwYKWRUlYm6k1IUQrZKKFS0TtRSUa6a1NqoWx4StutqPIXjsmimFqvy-YbRZmmvW5pq1uSY1lzhvVs40twOav4w_VSXAuxWA6fKdRd8EbZeojE2xxcaM9j_yjzVjtHs
CitedBy_id crossref_primary_10_1158_1078_0432_CCR_19_2741
crossref_primary_10_3390_vaccines11010146
crossref_primary_10_1051_jbio_2019002
crossref_primary_10_1016_S1470_2045_19_30068_3
ContentType Journal Article
Copyright 2018 THE AUTHORS
Copyright_xml – notice: 2018 THE AUTHORS
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
DOI 10.1093/annonc/mdy288.001
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
DatabaseTitle PubMed
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1569-8041
EndPage viii400
ExternalDocumentID 10_1093_annonc_mdy288_001
32137003
S0923753419495859
Genre Journal Article
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
0U7
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6I.
6J9
70D
AABJS
AABMN
AAEDW
AAESY
AAFTH
AAIAV
AAIYJ
AAJKP
AAJQQ
AAKAS
AAKUH
AAMVS
AAOGV
AAPNW
AAUQX
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABQTQ
ABSAR
ABSMQ
ABVKL
ABZBJ
ACGFO
ACGFS
ACIMA
ACMRT
ACPQN
ACPRK
ACUFI
ACUTO
ADBBV
ADEIU
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFIYH
AFOFC
AFXEN
AGINJ
AGKEF
AGKRT
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AITUG
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
AQKUS
ASMCH
ASPBG
ATTQO
AVWKF
AWCFO
AXUDD
AZFZN
AZQFJ
BAWUL
BAYMD
BEYMZ
BGNMA
BGYMP
BHONS
BTRTY
BVRKM
BZKNY
C1A
CAG
CASEJ
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DL5
DPORF
DPPUQ
D~K
E3Z
EBS
EE~
EJD
EX3
F9B
FDB
FEDTE
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
I09
IH2
IHE
IOX
J21
KAQDR
KC5
KDC
KOM
KOP
KQ8
KSI
KSN
LAK
M-Z
M41
M49
M4Y
MBLQV
MHKGH
N9A
NCXOZ
NGC
NOYVH
NTWIH
NU-
NU0
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RPX
RW1
RXO
RZC
RZE
RZF
RZO
SDH
TCURE
TEORI
TJX
TMA
TR2
U2A
W8F
WOQ
WOW
X7H
YAYTL
YFH
YKOAZ
ZKX
ZXP
~91
0SF
AALRI
ADVLN
AEHUL
AFETI
AFJKZ
AFSHK
AKRWK
H13
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c2781-4b22626487d7c51a27ecfabecfe36857ee4d66c533ba6a15b1396302c1cccda93
IEDL.DBID ABVKL
ISSN 0923-7534
IngestDate Thu Sep 26 15:44:31 EDT 2024
Wed Oct 16 00:46:55 EDT 2024
Fri Feb 23 02:48:13 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2781-4b22626487d7c51a27ecfabecfe36857ee4d66c533ba6a15b1396302c1cccda93
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0923753419495859
PMID 32137003
ParticipantIDs crossref_primary_10_1093_annonc_mdy288_001
pubmed_primary_32137003
elsevier_sciencedirect_doi_10_1093_annonc_mdy288_001
PublicationCentury 2000
PublicationDate October 2018
2018-Oct
2018-10-00
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: October 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Annals of oncology
PublicationTitleAlternate Ann Oncol
PublicationYear 2018
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0006929
Score 2.3168676
SourceID crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage viii400
Title Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients
URI https://dx.doi.org/10.1093/annonc/mdy288.001
https://www.ncbi.nlm.nih.gov/pubmed/32137003
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKKyEuiJZHCxTNgUMLsnbjJE5yLFWrLdAKUVr1FtmOXSJtHsom9PGb-RGMY29FL0XimMQvZUYz39gznwl5X6SaKxlxmqaxpFFgAiqkwkepwzRJM87GKv7jEz47iz5fxBcrZH9ZC2PTKr3tdzZ9tNb-zcT_zUlblpPTKWITBNsRhuEZgt7sEVljiH5R2df2Pp1_-XpnkHnGHOUeC6ntsDzczEJ710tTKwz-b1hqkyqDf7inv3zP4TPy1ING2HPrWicrut4gj4_9sfhz8vtbp6mtmSwNIkqwFBBdWYHwhCPQGBCATqloqvIWG7Q_0XfB0ZGE8dIO-73vxKIfbodKSPgItZ6Xrc13qYaensLOiR7OxfUu_Frca4iAFxBAQut5oJraDtXZLfyxiBAKXVn8aekoFiDRrJqyx-XZadu5xmkuR95x2JkdfGcwb66ovnaZufXlLkibMN-DsorZgWeAXbwgZ4cHP_Zn1F_jQBVLUoxQJUI8m0iXFImKA8ESrYxA3THast8nWkcF5wpxpxRcBLFEUMrDKVOBUqoQWfiSrKKU9CaB1CCgjbIiMlMZTQuRmkJLjPgSo1QQ63CLfFhKL28dW0fuTtnD3Ik6d6K2qXxbJFrKN7-ncjl6k4e6vXK6cDdDyIIwQev4-v8GfEOeIApzJLvBW7Lad4PeRqTTy3dek_8A12AE_g
link.rule.ids 315,783,787,27583,27938,27939,45677
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtRAEG2FRAIuETsJWx04JCBrxm6vxxAlmiEzI0QW5Wb1GiyNF3lsCPlmPoJqd09ELiBxtN2bXKWqV91Vrwl5L1MVCx7GXppG3At97XuMC3zkiqZJmsXBUMU_X8ST8_DzZXS5QQ7XtTAmrdLZfmvTB2vt3ozc3xw1RTE6HSM2QbAdYhieIejN7pEtRAMJRmBbB58uTma3BjnOAku5F1DPdFgfbmbU3PVSVwKD_59BapIq_X-4pz98z_Ejsu1AIxzYdT0mG6p6Qu7P3bH4U_LrS6s8UzNZaESUYCgg2qIE5ghHoNbAAJ2SrMviBhs039B3wXTKYbi0w3zvWrbq-pu-ZBw-QqWWRWPyXcq-805hb6H6C3a9D99Xdxoi4AUEkNA4Hqi6MkO1Zgt_KCIEqUqDPw0dxQo4mlVddLg8M22zVDjN1cA7DnuTo68BLOsfnrq2mbnV1T5wkzDfgTCK2YJjgF09I-fHR2eHE89d4-CJIEkxQuUI8UwiXSITEfksSJTQDHVHK8N-nygVyjgWiDs5i5kfcQSlMR0HwhdCSJbR52QTpaReEkg1Atowk6Ee83AsWaql4hjxJVoIP1J0h3xYSy9vLFtHbk_ZaW5FnVtRm1S-HRKu5ZvfUbkcvcnfur2wunA7Aw18mqB13P2_Ad-RB5Oz-SyfTRcnr8hDRGSWcNd_TTa7tldvEPV0_K3T6t8-mAfs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pre-specified+interim+analysis+of+a+randomized+phase+IIb+trial+of+trastuzumab+%2B+nelipeptimut-S+%28NeuVax%29+vs+trastuzumab+for+the+prevention+of+recurrence+demonstrates+benefit+in+triple+negative+%28HER2+low-expressing%29+breast+cancer+patients&rft.jtitle=Annals+of+oncology&rft.au=Hale%2C+D.F.&rft.au=Mittendorf%2C+E.A.&rft.au=Brown%2C+T.A.&rft.au=Clifton%2C+G.T.&rft.date=2018-10-01&rft.pub=Elsevier+Ltd&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=29&rft.spage=viii400&rft.epage=viii400&rft_id=info:doi/10.1093%2Fannonc%2Fmdy288.001&rft.externalDocID=S0923753419495859
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon